Enhancer of zeste homolog 2 (EZH2) in pediatric soft tissue sarcomas: first implications

Roberta Ciarapica1*, Lucio Miele2, Antonio Giordano3,4, Franco Locatelli1,5 and Rossella Rota1*

Abstract
Soft tissue sarcomas of childhood are a group of heterogeneous tumors thought to be derived from mesenchymal stem cells. Surgical resection is effective only in about 50% of cases and resistance to conventional chemotherapy is often responsible for treatment failure. Therefore, investigations on novel therapeutic targets are of fundamental importance. Deregulation of epigenetic mechanisms underlying chromatin modifications during stem cell differentiation has been suggested to contribute to soft tissue sarcoma pathogenesis. One of the main elements in this scenario is enhancer of zeste homolog 2 (EZH2), a methyltransferase belonging to the Polycomb group proteins. EZH2 catalyzes histone H3 methylation on gene promoters, thus repressing genes that induce stem cell differentiation to maintain an embryonic stem cell signature. EZH2 deregulated expression/function in soft tissue sarcomas has been recently reported. In this review, an overview of the recently reported functions of EZH2 in soft tissue sarcomas is given and the hypothesis that its expression might be involved in soft tissue sarcomagenesis is discussed. Finally, the therapeutic potential of epigenetic therapies modulating EZH2-mediated gene repression is considered.

Keywords: EZH2, soft tissue sarcomas, epigenetics, methylation, methyltransferases

Introduction
Soft tissue sarcomas: a clinical challenge
Soft tissue sarcomas (STSs) are a group of heterogeneous malignant neoplasms thought to arise from molecular lesions occurring during the differentiation of mesenchymal stem cells (MSCs) [1]. STSs account for less than 1% of all adult tumors and for about 15% of all pediatric ones, with an estimated 10,520 new cases in the US in 2010 [2,3]. A series of chromosomal translocations have been identified as hallmarks of most STSs, such as t(X;18)(p11.2;q11.2) in synovial sarcoma, t(11;22)(q24;q12) in Ewing’s sarcoma, t(2;13)(q35;q14) and t(1;13)(p36;q14) in alveolar rhabdomyosarcoma (RMS). These chromosomal rearrangements result in oncogenic fusion proteins that play direct roles in altering gene expression pattern in STS, promoting tumor aggressiveness. Because of their infiltrating behavior, only 50% of STSs are suitable for radical surgical resection. Moreover, a fraction of STSs are resistant to chemotherapeutic agents, especially the metastatic forms [4]. Doxorubicin, the drug used in standard single-agent chemotherapy protocols for the treatment of metastatic STS, results in only 20% to 25% response rates. Even the combination of doxorubicin with other agents, such as ifosfamide, has not dramatically improved the overall 5-year survival rate, which is no higher than 50% to 60% [4]. Nevertheless, chemotherapy represents the only viable strategy for palliation of symptoms in patients with metastatic disease, improving their quality of life [5]. New promising biological drugs, such as monoclonal antibodies to insulin-like growth factor receptor (IGFR), inhibitors of multityrosine kinases, and mammalian target of rapamycin (mTOR), have been introduced in STS clinical trials (Table 1) [4]. However, disease stabilization is still not seen in many patients, especially those affected by peculiar histological variants or showing poor-risk factors; it is reasonable to hypothesize that a combination of cytotoxic chemotherapy with targeted agents may be more appropriate to improve outcome in STS patients. A novel class of therapeutic targets is
| Biological molecular agents | Molecular target(s) | Clinical studies (phase) and clinical efficiency | Reference |
|-----------------------------|---------------------|--------------------------------------------------|------------|
| Tyrosine kinase inhibitors (TKIs) | &nbsp; | &nbsp; | *|
| Imatinib mesylate (IM) | c-Kit, PDGFR | Phase II study: 53.7% of patients with GISTs showed a partial response, 27.9% of patients showed stable disease, 13.6% of patients showed early resistance to imatinib, 5% of patients showed serious adverse events | [60] |
|  |  | Phase III study: confirmation of the effectiveness of imatinib as primary systemic therapy for patients with incurable GIST. No advantages to higher dose treatment were reported. | [61] |
| Sunitinib malate (SM) | VEGF-R1, VEGF-R2, VEGF-R3, c-Kit, PDGFR, Flt-3, CSF1, neurotrophic factor receptors | Phase III study: 7% of patients with GIST showed partial response, 58% had stable disease, 19% had progressive disease; 27.3 weeks was the time-to-tumor progression for sunitinib vs 6.4 weeks for placebo. Progression-free survival was similar. | [62] |
|  |  | Phase II study: 3-month progression-free rate of >40% for liposarcomas and leiomyosarcomas | [63] |
|  |  | Phase II study: 52% of patients showed metabolic stable disease, 20% of patients achieved stable disease for at least 16 weeks, 47% of patients achieved partial response | [64] |
|  |  | Phase II study (current): SM activity in patients with certain subtypes of STS. The majority of these patients showed stable disease for 16 weeks. | [65] |
| Sorafenib | VEGF-R2, VEGF-R3, c-Kit, PDGFR, Raf/Mek/Erk | Phase II study: 14% of patients with angiosarcoma and 6% of patients with leiomyosarcoma had a response, 64% of patients developed intolerance at the drug dose used | [66] |
|  |  | Phase II study: 78% patients with vascular tumors showed disease stabilization | [67] |
|  |  | Phase II study (current): antitumor activity and acceptable toxicity profile in patients with antracycline-refractory STS | [68] |
| Pazopanib | VEGF-Rs | Phase II study: 12-week progression-free survival was reached by 44% patients with leiomyosarcoma, 49% of patients with synovial sarcomas, and 39% of patients with the other STS types | [69] |
| Nilotinib | BCR/ABL, c-Kit, PDGFR, CSF1R | Phase I study: nilotinib alone or in combination with imatinib was well tolerated and showed clinical activity in imatinib-resistant GIST patients | [70] |
| Mammalian target of rapamycin (mTOR) inhibitors | &nbsp; | &nbsp; | *|
| Tensirolimus | mTOR | Phase II study: moderate toxicity and limited clinical activity | [71] |
| Everolimus | mTOR | Phase II study: acceptable toxicity. Limited clinical activity in heavily pretreated patients with bone and soft tissue sarcomas. The efficacy in imatinib-refractory and sunitinib-refractory GIST is promising. | [72] |
| Ridaforolimus (AP23573) | mTOR | Phase I study: safety of the drug; 27% of patients showed stable disease. | [73] |
|  |  | Phase II study: 29% of clinical benefit rate. Prolongation of survival. | [74] |
|  |  | Phase III study (current) | [75] |
| Insulin-like growth factor (IGF) receptor antibodies | &nbsp; | &nbsp; | *|
| Figitumumab | IGF-1R | Phase I study: good tolerance of the drug | [76] |
| R1507 | IGF-1R | Phase II study (current): R1507 is well tolerated. Significant activity has been observed in Ewing’s sarcoma, RMS and OS with several dramatic responses seen in Ewing’s sarcoma and RMS. | [77] |
| AMG479 | IGF-1R | Phase I study: absence of severe toxicities | [78] |
| Mk-0646 | IGF-1R | Phase I study (current) | [79] |

CSF1 = colony stimulating factor 1; Flt = fms-related tyrosine kinase; GIST = gastrointestinal stromal tumor; OS = osteosarcoma; PDGFR = platelet-derived growth factor receptor; RMS = rhabdomyosarcoma; VEGF = vascular endothelial growth factor.
represented by epigenetic regulators, such as DNA methyltransferases (DNMTs), histone acetylases (HATs), histone deacetylases (HDACs), and histone methyltransferases (HMTs). Physiologically, all these enzymes work in concert for regulating gene expression by modifying the state of chromatin without altering DNA gene sequences in order to obtain a proper tissue determination. Increasing evidence demonstrates that they play key roles in human tumorigenesis, often being deregulated in terms of expression and/or activity and leading to silencing of essential regulators of cell proliferation and differentiation. Indeed, from comparative analyses, it appears that cancer genomes show different patterns of epigenetic modifications as compared to normal cells. Using inhibitory agents of all of these enzymes, it is possible to obtain pharmacological reversion of the tumor-specific gene expression profile, as well as reactivation of abnormally silenced tumor-suppressor genes in cancer cells [6]. Among these regulatory players, the histone methyltransferase enhancer of zeste homolog 2 (EZH2) is considered one of the most appealing epigenetic targets for therapy in human cancer [7].

The Polycomb group protein EZH2 in STS

EZH2 is one of the Polycomb group (PcG) proteins, which repress expression of developmentally regulated genes that induce tissue differentiation, such as homeotic genes. PcG proteins help maintaining the undifferentiated, multipotent phenotype of the embryonic stem cell compartment [7-11]. In vertebrates, PcG proteins form two different groups of multiprotein Polycomb repressor complexes (PRCs), PRC1 and PRC2/3. EZH2 is the catalytic unit of the PRC2/3 complex, the part involved in the initiation of gene repression. EZH2 methylates lysine 27 of histone H3, thus generating the H3K27-trimethylated epigenetic mark that is recognized by the PRC1 complex for further, long-term chromatin modifications (Figure 1a) [8]. EZH2 is promptly downregulated during progenitor cell differentiation, becoming undetectable in adult specialized cells and tissues (Figure 1b) [12]. Conversely, EZH2 is abnormally overexpressed in a wide range of tumors as compared with corresponding normal tissues, its level of expression being correlated with cancer aggressiveness [7,13,14]. Moreover, the abundance of EZH2 molecules induces the formation of more repressor complexes and, by altering the balance between different PcG components, may lead to the formation of tumor-specific PRC complexes that show differential substrate specificities [15]. As a result, not only the general level of repression but also the specificity of repressed genes is changed. EZH2 has recently been found aberrantly expressed in aggressive and poorly differentiated breast and prostate carcinomas [13,14], as well as in STS [16,17]. EZH2 aberrant overexpression may be one of the molecular lesions occurring in differentiating mesenchymal stem cells (MSCs), which are thought to be the cells of origin of STS [1]. It has been proposed that the presence of EZH2 in tumors with embryonal features and stem-cell phenotype, such as STS, may explain their undifferentiated and immature character. In view of these data, EZH2 appears to be an attractive target for investigation in STS.

EZH2 in RMS

RMSs are a heterogeneous group of STSs characterized by features of skeletal muscle tissue and thought to be caused by abnormalities occurring during the course of myogenesis [18,19]. It prevalently affects pediatric patients and accounts for almost 50% of all STSs [20]. Classically, RMSs are histologically subdivided in two subtypes: the alveolar and embryonal forms. More recently, it has been reported that a diagnosis of alveolar RMS can be made only in the presence of two specific molecular aberrations, namely t(2;13)(q35;q14) and/or t(1;13)(p36;q14) chromosomal translocations resulting in PAX3-FKHR and the rarer PAX7-FKHR oncogenic fusion proteins, respectively [21]. These lesions have been found in about 20% of all RMSs and in about 70% of the RMSs with an alveolar histology [21,22]. True alveolar RMSs are often metastatic at diagnosis, show unresponsiveness to conventional therapy and have poor prognosis, the long-term survival rate being < 25% [23,24]. Fusion-negative RMSs include tumors with embryonal histology and the remaining part of RMSs with an alveolar histology [18]. Evidence for aberrant overexpression of EZH2 in RMS samples has been reported by Wang and colleagues [25] and by our studies in RMS cell lines and primary samples [16]. We have recently confirmed this finding in a large cohort of RMS specimens, documenting that overexpression of EZH2 is a hallmark of RMS, independently of the histological subtype [26]. It remains to be determined whether the level of EZH2 expression correlates with the presence of fusion proteins typical of the alveolar subtype. These results are consistent with the observation that in a physiological context EZH2 inhibits muscle differentiation of normal myoblasts by silencing muscle-specific genes [27]. Among these genes are those encoding for promyogenic microRNAs, such as miR-214 and miR-29. These belong to a class of small RNAs that inhibits the translation of selected mRNAs thus preventing their protein expression [25,28]. Mir-26a is another microRNA acting to post-transcriptionally repress EZH2 in normal myoblasts undergoing differentiation (Figure 2a left panel) [29]. During differentiation, miR-29 is induced and targets the PcG transcription factor yin yang 1 (YY1) mRNA promoting its degradation (Figure 2a left panel). In the absence of a myogenic stimulus and in RMS cells, EZH2
is recruited together with HDAC1 by YY1 to repress transcription of both myofibrillary genes [27,30] and miR-29 (Figure 2a right panel) [25]. Similarly, miR-214 is directly repressed by EZH2 in undifferentiated committed myoblasts and, in turn, it is able to bring about negative feedback on EZH2 during myogenesis by targeting its transcript [28]. A role for miR-26a and miR-29 in RMS pathogenesis was confirmed by recent studies [16,25]. We found that miR-26a is aberrantly downregulated in RMS cell lines and primary tumors as compared to non-tumor counterparts, and that miR-26a loss of expression is paralleled by an overexpression of EZH2 [16]. Similarly, miR-29 levels are reduced in tumor samples as compared with control muscle tissues. This finding can be interpreted considering that overexpressed EZH2 and YY1 are capable to repress miR-29 transcription in RMS cells (Figure 2a).
In agreement with the above observations, it has been found that miR-29 ectopic expression promotes RMS cell-cycle arrest, myogenic cell differentiation and tumor growth inhibition in a xenograft model [25]. Reduction of miR-29 levels had been previously reported in a small cohort of alveolar RMS [31]. Altogether, these findings provide evidence for a key role of EZH2-mediated epigenetic changes in RMS pathogenesis, which involve also mutual interactions with microRNAs.

EZH2 in synovial sarcoma
Synovial sarcoma is a malignant cancer that affects prevalently young patients and represents almost 10% of all STSs [32]. It is characterized by the typical translocation t(X;18)(p11;q11) that generates the fusion between the synovial sarcoma translocation, chromosome 18 (SS18 or SYT) gene on chromosome 18 and either synovial sarcoma, X breakpoint 1, 2 or 4 (SSX1, SSX2 or SSX4) genes on the X chromosome [33]. Previously reported data showed that chimerical proteins SYT-SSX might disrupt gene expression mechanisms by functionally interacting with PcG proteins in synovial cells [34]. In particular, SYT-SSX2 fusion protein induces downstream target-gene deregulation through epigenetic mechanisms [35]. Recently, EZH2 has been found to mediate the effects of SYT-SSX activity. Specifically, SYT-SSX2 represses the expression of the tumor suppressor gene early growth response 1 (EGR1), a regulator of cell cycle, engaging EZH2 on the EGR1 promoter in synovial sarcoma cells (Figure 2b). EGR1 repression...

![Figure 2 Possible mechanisms of deregulation of enhancer of zeste homolog 2 (EZH2) in soft tissue sarcoma (STS). (A) In normal differentiating myoblasts (left panel) promyogenic miR-26a and miR-29 are normally expressed. MiR-26a and miR-29 target EZH2 and yin yang 1 (YY1) mRNAs, respectively, at the 3' untranslated region (UTR) to induce their degradation. Conversely, in rhabdomyosarcoma (RMS) cells (right panel) promyogenic miRNAs are downregulated and their loss of function is paralleled by the overexpression of EZH2 and YY1. YY1 recruits EZH2 to repress the expression of miR-29, establishing a negative regulatory feedback loop. (B) In synovial sarcoma, the chimerical transcription factor SYT-SSX engages EZH2 that leads to H3K27 trimethylation silencing tumor suppressor genes such as early growth response 1 (EGR1). (C) In Ewing’s sarcoma the chimerical transcription factor Ewing sarcoma (EWS)/Friend leukemia integration 1 (FLI1) directly contributes to the maintenance of high level of expression of EZH2.](image-url)
Strikingly, EWS/FLI1 has been found to induce the expression signature, inhibiting differentiation [17]. Richter and colleagues found that EZH2 is expressed at high levels in Ewing’s tumors [17]. Studying the influence of EZH2 downregulation on gene expression, Richter and colleagues found that EZH2 is responsible for the undifferentiated phenotype of Ewing’s sarcoma by maintaining a stemness gene expression signature, inhibiting differentiation [17]. Strikingly, EWS/FLI1 has been found to induce the expression of EZH2 by direct binding to its promoter in both Ewing’s sarcoma cell lines and human MSCs (Figure 2c) [17]. EWS/FLI1-dependent activation of EZH2 seems to be specific, because the other components of the PRC2/3 complex are not affected [38]. Notably, human MSCs seem to represent a permissive environment for the expression of EWS/FLI1, which induces features in these cells that recapitulate Ewing’s sarcoma biology. This observation may implicate EZH2 as a coinitiator of Ewing’s sarcoma [39]. Data from these studies offer an example of how a translocation-derived fusion product takes advantage of EZH2 recruiting this methyltransferase to drive tumor progression at the expenses of differentiation.

**Concluding remarks and future perspectives**

Pediatric STSs, especially those metastatic at diagnosis, are highly aggressive tumors for which there is still an unmet medical need of more effective and less toxic therapeutic approaches. The role of the epigenetic regulator EZH2 in maintaining the embryonal cell phenotype of STS, its overexpression in these cancers and its functional interaction with many fusion proteins typical of STS, suggest that EZH2 may represent both a potential marker of undifferentiated precancerous cells and a reasonable candidate therapeutic target in STS. Increasing attention is focusing on epigenetic therapies that have provided promising results in clinical trials for some human tumors [40-42]. The clinical effectiveness of epigenetic therapies in human malignancies has been recently proved by the observation that, in a randomized phase III trial, the DNA hypomethylating agent azacytidine prolonged overall survival of myelodysplastic syndrome (MDS) patients compared to other standard therapies [43]. The potential efficacy of epigenetic therapy in STS is supported by preclinical studies employing HDAC inhibitors [36,44-46]. Many studies on cell culture and animal models indicate that diverse epigenetic processes synergize to control gene expression. Hence, different kinds of epigenetic drugs, such as DNA-demethylating agents and HDAC inhibitors, have been included in combination treatment protocols [40,47]. It is noteworthy that, in Ewing’s sarcoma cells, HDAC inhibitor treatment in vitro induces downregulation of EZH2 [17], as more recently confirmed in glioma [48], gallbladder carcinoma [49] and acute myeloid leukemia [50]. Consistently, in preclinical models of different cancers, the antitumor effect of EZH2 inhibition, obtained through the methyltransferase inhibitor 3′-deazaneplanocin (DZNep), is enhanced by addition of HDAC inhibitors [51-53]. DZNep has been shown to act by causing depletion of PRC2 subunits with subsequent reactivation of PRC2-silenced genes [54,55]. In this view, additional usage of DNMTs inhibitors in protocols targeting EZH2 might improve response in some tumor contexts. In turn, since HMTs are also active in non-proliferating cells, the inclusion of EZH2 inhibitors in combination regimens may overcome the ineffectiveness of DNMTs inhibitors in quiescent cells. On the other hand, it must be noted that, due to the complexity of molecular crosstalk involved in epigenetic control, the use of epigenetic drugs affecting a variety of molecular networks entails the risk of unforeseeable effects. For instance, despite their antiproliferative effects in vitro, treatments employing either HDACs or DNA methylation inhibitors have been recently reported to increase in vivo the invasive capabilities of RMS cells through upregulation of the prometastatic gene Ezrin [57]. Major questions remain open on the in vivo mechanism(s) of action of epigenetic drugs. Indeed, the clinical response to azacytidine in terms of prolongation of survival in MDS patients does not appear to be directly correlated with methylation of specific tumor suppressor genes, though methylation status has been shown to correlate with poor survival [58]. Even if future preclinical studies will better clarify the mechanisms of action of these drugs on gene expression, preclinical findings will need to be validated in humans [59].

Despite these unresolved questions, epigenetic therapy is a promising approach for targeted anticancer therapies in pediatric STS. Available evidence suggests that targeting the methyltransferase EZH2 may be potentially
able to restore physiological patterns of gene expression in pediatric STS. In the future, modulation of EZH2 activity may provide a new line of intervention that could be combined with epigenetic drugs acting on other molecular targets and/or conventional cytotoxic agents to treat these aggressive pediatric tumors.

Acknowledgements
The present work was supported by grants from Ministero della Sanità Italia (Ricerca Corrente), Associazione Italiana per la Ricerca sul Cancro (AIRC) Project 10338 and Istituto Superiore di Sanità (ISS Project 70B/F/8) to RR and by grants from Ministero della Salute, Italia (Ricerca Corrente) and AIRC (Special Project 5 × mille) to FL.

Author details
1Department of Oncohematology, IRCCS, Ospedale Pediatrico Bambino Gesù, Roma, Italy. 2Cancer Institute, University of Mississippi Medical Center, Jackson, MS, USA. 3Isbaro Institute for Cancer Research and Molecular Medicine, Temple University, Philadelphia, PA, USA. 4Department of Human Pathology and Oncology, Università di Siena, Siena, Italy. 5Dipartimento di Scienze Pediatriche, Università di Pavia, Pavia, Italy.

Authors’ contributions
RC and RR contributed equally to selection and discussion of the literature and the conception and preparation of the manuscript. FL, AG and LM contributed to the discussion on clinical implications and reviewed the manuscript. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 2 February 2011 Accepted: 25 May 2011 Published: 25 May 2011

References
1. Siddiqui S, Mills J, Matuhashinsky I: Epigenetic remodeling of chromatin architecture: exploring tumor differentiation therapies in mesenchymal stem cells and sarcomas. Curr Stem Cell Res Ther 2010, 5:63-73.
2. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
3. Vincenzi B, Frezza AM, Santini D, Tonini G: New therapies in soft tissue sarcoma. Expert Opin Emerg Drugs 2010, 15:237-248.
4. Ganjoo KN: Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcoma. Cancer Res 2006, 66:6936-6946.
5. Kriekels D, Judson I: Role of chromotherapy in the management of soft tissue sarcomas. Expert Rev Anticancer Ther 2010, 10:249-260.
6. Yoo CB, Jones PA: Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006, 5:37-50.
7. Simon JA, Lange CA: Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 2008, 647:21-29.
8. Sparmann A, van Louhoven M: Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 2006, 6:846-856.
9. Ringrose L, Furo H: Epigenetic regulation of cellular memory by the Polycomb and Trithorax group proteins. Annu Rev Genet 2004, 38:413-443.
10. Rajasekhar VR, Begemann M: Concise review: roles of polycomb group proteins in development and disease: a stem cell perspective. Stem Cells 2007, 25:2498-2509.
11. Bhatia M, Chennakesavan S, Gehrke E, Haldar S, Regulski M, Fraternalio G, Sartorelli V: YY1-miR-29 regulatory circuitry in skeletal myogenesis and CD31 expression in human pediatric rhabdomyosarcoma. Abstract #3417: Ezh2 is up-regulated and correlates with Ki67 and cellular biology of rhabdomyosarcoma. Future Oncol 2009, 5:1449-1457.
12. Caretti G, Di Padova M, Micales B, Lyons GE, Sartorelli V: Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcoma. Cancer Res 2006, 66:6936-6946.
13. Lue M, Ahn EH, Mercado GE, Chuai S, Edgar MJ, Pawel BR, Oshen A, Barr FG, Ladanyi M: Global gene expression profiling of PAX-FKHR fusion-negative alveolar and PAX-FKHR fusion-positive embryonal rhabdomyosarcomas. J Pathol 2007, 212:143-151.
14. Wang H, Garzon R, Sun H, Ladner KJ, Singh R, Rahman M, Cheng A, Hall BM, Quaim SJ, Chandler DS, Core E, Guttridge DC: NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell 2008, 14:369-381.
15. Caretti R, Pozzulo M, Verginelli F, Boldrini R, Sio LD, Stolfi S, Giordano A, Rota R: Abstract #3417: Ezh2 is up-regulated and correlates with Ki67 and CD31 expression in human pediatric rhabdomyosarcoma. AACR Meeting Abstracts American Association for Cancer Research, Philadelphia, PA, 2010.
16. Caretti G, Di Padova M, Micales B, Lyons GE, Sartorelli V: The Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation. Genes Dev 2004, 18:2627-2638.
17. Yuan AH, Kumar RM, Marx JG, Young RA, Sartorelli V: Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res 2006, 66:6936-6946.
18. Lue M, Ahn EH, Mercado GE, Chuai S, Edgar MJ, Pawel BR, Oshen A, Barr FG, Ladanyi M: Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas. J Pathol 2007, 212:143-151.
19. Wang H, Garzon R, Sun H, Ladner KJ, Singh R, Rahman M, Cheng A, Hall BM, Quaim SJ, Chandler DS, Core E, Guttridge DC: NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell 2008, 14:369-381.
20. Caretti R, Pozzulo M, Verginelli F, Boldrini R, Sio LD, Stolfi S, Giordano A, Rota R: Abstract #3417: Ezh2 is up-regulated and correlates with Ki67 and CD31 expression in human pediatric rhabdomyosarcoma. AACR Meeting Abstracts American Association for Cancer Research, Philadelphia, PA, 2010.
21. Carréti G, Di Padova M, Micales B, Lyons GE, Sartorelli V: The Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation. Genes Dev 2004, 18:2627-2638.
22. Yuan AH, Kumar RM, Marx JG, Young RA, Sartorelli V: Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res 2006, 66:6936-6946.
23. Lue M, Ahn EH, Mercado GE, Chuai S, Edgar MJ, Pawel BR, Oshen A, Barr FG, Ladanyi M: Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas. J Pathol 2007, 212:143-151.
24. Wang H, Garzon R, Sun H, Ladner KJ, Singh R, Rahman M, Cheng A, Hall BM, Quaim SJ, Chandler DS, Core E, Guttridge DC: NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell 2008, 14:369-381.
25. Caretti R, Pozzulo M, Verginelli F, Boldrini R, Sio LD, Stolfi S, Giordano A, Rota R: Abstract #3417: Ezh2 is up-regulated and correlates with Ki67 and CD31 expression in human pediatric rhabdomyosarcoma. AACR Meeting Abstracts American Association for Cancer Research, Philadelphia, PA, 2010.
26. Caretti G, Di Padova M, Micales B, Lyons GE, Sartorelli V: The Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation. Genes Dev 2004, 18:2627-2638.
27. Yuan AH, Kumar RM, Marx JG, Young RA, Sartorelli V: Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res 2006, 66:6936-6946.
28. Lue M, Ahn EH, Mercado GE, Chuai S, Edgar MJ, Pawel BR, Oshen A, Barr FG, Ladanyi M: Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas. J Pathol 2007, 212:143-151.
29. Wang H, Garzon R, Sun H, Ladner KJ, Singh R, Rahman M, Cheng A, Hall BM, Quaim SJ, Chandler DS, Core E, Guttridge DC: NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell 2008, 14:369-381.
30. Caretti R, Pozzulo M, Verginelli F, Boldrini R, Sio LD, Stolfi S, Giordano A, Rota R: Abstract #3417: Ezh2 is up-regulated and correlates with Ki67 and CD31 expression in human pediatric rhabdomyosarcoma. AACR Meeting Abstracts American Association for Cancer Research, Philadelphia, PA, 2010.
32. Okcu MF, Despa S, Chorozcy M, Berrak SG, Canger A, Jaffe N, Raney RB: Synovial sarcoma in children and adolescents: thirty three years of experience with multimodal therapy. Med Pediatr Oncol 2001, 37:90-96.
33. Jain S, Xu R, Pretto VG, Lee P: Molecular classification of soft tissue sarcomas and its clinical applications. Int J Clin Exp Pathol 2010, 3:416-428.
34. Soulez M, Saurin AJ, Freemont PS, Knight JC: SXX and the synovial-sarcoma-specific chimaeric protein SXT-SXX co-localize with the human Polycomb group complex. Oncogene 1999, 18:2739-2746.
35. de Bruijn DR, Allander SV, van Dijk AH, Willemse MP, Trijbels JF, van Groningen JJ, Meltzer PS, van Kessel AG: The synovial-sarcoma-associated SS18-SSX2 fusion protein induces epigenetic gene (de)regulation. Cancer Res 2006, 66:9474-9482.
36. Lubieniecka JM, de Bruijn DR, Su L, van Dijk AH, Subramanian S, van de Rijn M, Poulin N, van Kessel AG, Nielsen TO: Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma. Cancer Res 2008, 68:4303-4310.
37. Erkizan HV, Uversky VN, Toretsky JA: Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing’s sarcoma. Clin Cancer Res 2010, 16:4077-4083.
38. Burdach S, Plehm S, Unland R, Dirksen U, Borkhardt A, Staege MS, Muller-Merbach M: Protein interactions initiate key pathways of Ewing’s sarcoma initiation program in human mesenchymal stem cells. Cancer Res 2008, 68:2176-2185.
39. Tuma RS, Nakamura T, Matsumoto Y, Iwamoto Y, Sakimura R, Tanaka K, Nakatani F, Matsunobu T, Li X, Hanada M, Okada T, Yu Y, Zeng P, Xiong J, Liu Z, Berger SL, Merlino G: Histone deacetylase inhibitor panobinostat against human AML cells. Leuk Lymphoma 2009, 50:221-229.
40. Raymond AK, Bramwell VH, Baker LH, Maki RG, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumours who have failed imatinib: a randomised controlled trial. Lancet 2006, 368:1329-1338.
41. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006, 368:1329-1338.
42. Fiskus W, Wang Y, Sreekumar A, Buckley KM, Shi H, Jellila A, Ustun C, Lee P, Koul S, Balusu R, Peng B, Dimitrijevic S, Blanke CD, Rankin C, Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG: Efficacy and safety of sunitinib in patients with unresectable or metastatic gastrointestinal stromal tumours expressing the kit receptor tyrosine kinase: 500363. J Clin Oncol 2008, 26:626-632.
43. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006, 368:1329-1338.
44. Yamaguchi S, Saiaki M, Sato Y, Iwatsuka K, Harada K, zen Y, Ikeda H, Nimura Y, Nagino M, Nakamura Y: Histone deacetylase inhibitor (SAHA) and repression of EZH2 synergistically inhibit proliferation of gallbladder carcinoma. Cancer Sci 2010, 101:355-362.
45. Fiskus W, Buckley K, Rao R, Nandavat A, Yang Y, Joshi R, Wang Y, Balusu R, Chen J, Kou S, Joshi A, Upadhyay S, Atadja P, Bhalla KN: Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells. Cancer Biol Ther 2009, 8:939-950.
46. Hayden A, Johnson PW, Packham G, Crab SJ: 5-adenosylhomocysteine hydroxide inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition. Breast Cancer Res Treat .
47. Kalužská M, Frynkas M, Lemaire M, Fristedt C, Agarwal E, Eriksson M, Deleu S, Atadja P, Osterberg A, Nilsson K, Vanderkerken K, Oberg F, Jørgensen-Wiklund H: Polycomb target genes are silenced in multiple myeloma. PLoS One 2010, 5:e11483.
48. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumours who have failed imatinib: a randomised controlled trial. Lancet 2006, 368:1329-1338.
of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol 2009, 27:3154-3160.

65. Keohan ML, Morgan JA, D’Adamo DR, Harmon D, Butynski JE, Wagner AJ, Schwartz GK, Maki RG, Demetri GD, George S: Continuous daily dosing (CDD) of sunitinib (SU) in patients with metastatic soft tissue sarcomas (STS) other than GIST: Results of a phase II trial. In ASCO Meeting Abstracts. Volume 26. American Society of Clinical Oncology, Alexandria, VA; 2008(Suppl):10333.

66. Maki RG, Keohan ML, Undevia SD, Livingston M, Cooney MM, Elia A, Saulle MF, Wright JJ, D’Adamo DR, Schuetze SM. Sarofenib Sarcoma Study Group: Update of results of a phase II study of oral multikinase inhibitor sorafenib in soft tissue sarcomas, CTOP study #7060. In ASCO Meeting Abstracts. Volume 26. American Society of Clinical Oncology, Alexandria, VA; 2008(Suppl):10331.

67. Ryan CW, von Mehren M, Rankin CJ, Goldblum JR, Demetri GD, Bramwell VH, Borden EC: Phase II intergroup study of sorafenib (S) in advanced soft tissue sarcomas (STS): SWOG 0505. In ASCO Meeting Abstracts. Volume 26. American Society of Clinical Oncology, Alexandria, VA; 2008(Suppl):10332.

68. Bertuzzi A, Stroppa EM, Secondino S, Pedrazzoli P, Zucali P, Quagliuolo V, Comandone A, Basso U, Soto Parra HJ, Santoro A: Efficacy and toxicity of sorafenib monotherapy in patients with advanced soft tissue sarcoma failing anthracycline-based chemotherapy. In ASCO Meeting Abstracts. Volume 28. American Society of Clinical Oncology, Alexandria, VA; 2010(Suppl):10025.

69. Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schöffski P, Collin F, Bramwell VH, Borden EC, De Brauwer A, van Glabbeke M, Verweij J, Bay JY: Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 2009, 27:3126-3132.

70. Demetri GD, Casali PG, Blay JY, von Mehren M, Morgan JA, Bertulli R, Ray-Coquard I, Cassier P, Davey M, Borghaei H, Pink D, Debetz-Rychter M, Cheung W, Bailey SM, Verweij J, Loewy J, Kan R, Demetri GD: A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res 2009, 15:5910-5916.

71. Okuno S, Bailey H, Mahoney MR, Adkins D, Maples W, Fitch T, Ettinger D, Erlichman C, Sarkaria JN: A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: A study of the mTORC1 and 2 consortium (P2C). Cancer 2011.

72. Richter S, Pink D, Hohenberger P, Schuette H, Casali PG, Pustowka A, Reichardt P: Multicenter, triple-arm, single-stage, phase II trial to determine the efficacy and safety of everolimus (RAD001) in patients with refractory bone or soft tissue sarcomas including GIST. In ASCO Meeting Abstracts. Volume 28. American Society of Clinical Oncology, Alexandria, VA; 2010(Suppl):10076.

73. Mita MM, Britten CD, Poplin E, Tap WD, Carmona A, Yonemoto L, Pandite L, Marreaud S, De Brauwer A, van Glabbeke M, Fitch T, Zhu M, Deng H, Friberg G, Puzanov I: Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 2009, 27:5800-5807.

74. Schnitzler M, Bianconi M, Maccarone E, Giampieri R, Berardi R, Casini S, Dalotuzumab, a recombinant humanized mAb targeted against IGFIR1 for the treatment of cancer. Curr Opin Mol Ther 2010, 12:361-371.